Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 15, 2024 - Singular Genomics Systems, Inc.(Nasdaq: OMIC), a company specializing in next-generation sequencing and spatial multiomics technologies, announced today that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
The company received formal notice from the Nasdaq Stock Market LLC (Nasdaq) confirming its compliance.This development reflects Singular Genomics’ strong financial performance and positive market outlook.
Furthermore, Singular Genomics Systems had previously revealed plans for a 1-for-30 reverse stock split.Effective June 26, 2024, the reverse split aimed to consolidate the company’s common stock and enhance its market position.The company’s common stock began trading on a split-adjusted basis under the symbol OMIC on the same day.
The reverse stock split was implemented to amplify Singular Genomics’ stock value, potentially attracting more investors and increasing its standing within the market.By reducing the number of outstanding shares, the company hoped to heighten the price per share.
Prior to the reverse stock split, Singular Genomics Systems had 73.178822 million shares outstanding, with a current price of $8.74 per share.After the split, the CUSIP number of the company’s common stock became 82933R 308.
This recent compliance restoration provides Singular Genomics with continued access to the Nasdaq Capital Market, ensuring its stock remains available for trading.The company’s ability to meet the minimum bid price requirement indicates its stability and reinforces investor confidence.
Singular Genomics Systems’ focus on leveraging next-generation sequencing and spatial multiomics technologies sets it apart from its competitors.By empowering researchers and clinicians with innovative tools and solutions, Singular Genomics aims to accelerate advancements in genomics research and improve patient outcomes.
Through this compliance achievement and reverse stock split, Singular Genomics Systems demonstrates its commitment to growth and success.With a strengthened market position, the company is well-positioned to continue making strides in the field of genomics and driving value for its shareholders.
Comments